Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Delirium 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Chlorpromazine × 1 year × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT05190315 2025-09-02

Chlorpromazine and Standard of Care in Glioblastoma

University of Iowa

Phase 1 Completed
10 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡